Here are five points:
1. Bank of America put a $56 price objective on NuVasive’s stock.
2. NuVasive shares traded up 1.94 percent to $52.55.
3. The company has a 12-month low of $41.52 and a 12-month high of $56.61.
4. NuVasive’s price-to-earnings ratio is 43.04 and its market cap is $2.58 billion.
5. The 50-day moving average is $50.83 and the 200-day moving average is $50.86.
More articles on devices:
Did Loma Linda’s orthopedic device rep-less strategy work? 5 things to know
Could the medical device excise tax actually go away in the tax cuts package? 5 key notes
Exactech director sells 1.5k shares — 5 facts
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
